Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.

Fairmount Funds Management LLC

Robinson John Edward

Sachs Jessica

Green John L.

Kearns Evan

Swing & day trader
Tweets are my opinion only and not a recommendation to buy or sell any security.
I don't Have any subservice/ WhatsApp group /Telegram group!

HODOR

Research and idea generation largely focused on small & mid-cap biotech and special situations.

Cogent Biosciences Inc (COGT) Stock Price, Analysis & Trade Signals